MoonLake Reports Strong Phase 3 Sonelokimab HS Results
ZUG, Switzerland, June 21, 2026 MoonLake Immunotherapeutics has announced compelling Week 52 results from its Phase 3 VELA clinical...
drug development
Advertisement
BioArctic, Lilly Partner on Next-Gen Brain Therapies
STOCKHOLM, Sweden, June 22, 2026 BioArctic AB and Eli Lilly and Company have entered into a major research and...
Insilico Medicine and SK Bio Launch $2.5B CNS Alliance
BOSTON, MA and SEOUL, South Korea, June 22 2026 Insilico Medicine and SK Biopharmaceuticals have announced a landmark artificial...
Mighty Therapeutics Announces New Era in Mitochondrial Medicine
BOSTON, June 22, 2026 Mighty Therapeutics, formerly known as Stealth BioTherapeutics, has officially announced its corporate rebranding, marking a...
CervoMed Secures $10 Million to Advance Brain Disease Pipeline
BOSTON, June 18, 2026 CervoMed Inc., a clinical-stage biotechnology company focused on developing therapies for age-related neurological disorders, has...
Advertisements
Avance Clinical Highlights Oncology Expertise at ASCO 2026
CHICAGO, Ill., June 20, 2026 Avance Clinical, a leading global Contract Research Organization (CRO) specializing in accelerating clinical development...
GSK and Spero Secure FDA Nod for First Oral Carbapenem
LONDON, United Kingdom, June 18, 2026 GSK plc and Spero Therapeutics have achieved a major milestone in the fight...
Biogen Signs Landmark RayThera Acquisition Worth Up to $1 Billion
CAMBRIDGE, Mass. and SAN DIEGO, June 17, 2026 Biogen Inc. has announced a strategic agreement to acquire RayThera Inc....
Insilico Medicine Reports First Human Dosing of ISM8969
HONG KONG, June 18, 2026 Insilico Medicine, a clinical-stage biotechnology company powered by generative artificial intelligence (AI), has announced...
Bristol Myers Squibb Declares Quarterly Dividend Payment
PRINCETON, N.J., June 17, 2026 Bristol Myers Squibb (BMS) has announced that its Board of Directors has declared a...
Advertisement
